Edition:
United Kingdom

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

2.54USD
12 Dec 2017
Change (% chg)

$0.03 (+1.20%)
Prev Close
$2.51
Open
$2.49
Day's High
$2.54
Day's Low
$2.45
Volume
3,136
Avg. Vol
6,619
52-wk High
$35.70
52-wk Low
$2.24

Summary

Name Age Since Current Position

Roger Hawley

63 2017 Independent Chairman of the Board

Sabrina Johnson

2017 President, Chief Executive Officer, Secretary, Director

Gregg Beloff

48 2017 Principal Financial Officer

Lisa Walters-Hoffert

2017 Chief Financial Officer

Jame O'Neill

52 2015 Principal Accounting Officer, Controller, Assistant Treasurer

William Rastetter

68 Lead Independent Director

Steve Hall

60 2010 Independent Director

Susan Kelley

62 2014 Independent Director

Robin Steele

58 2017 Independent Director

Biographies

Name Description

Roger Hawley

Mr. Roger L. Hawley serves as Independent Chairman of the Board of the company. Mr. Hawley has served as Chairman of the Board of Directors of Daré Operations since its inception in 2015. Mr. Hawley is an experienced pharmaceutical executive and director with more than 25 years of industry experience. He has held senior management roles in both private start-up companies as well as small to mid-sized public companies. His senior level experience includes executive management, finance and accounting, sales and marketing. During his career, Mr. Hawley was a member of the board of directors of two previously publicly-traded biopharmaceutical companies and has served in various executive positions involving commercial operations, partnership management, sales and corporate finance. From 1976 to 1987, Mr. Hawley held various financial management positions with Marathon Oil Company, including serving four years in London, England, at which time he was a certified treasury manager and a certified public accountant. From 1987 to 2001, Mr. Hawley held a broad range of management positions in commercial operations, alliance/partnership management, regional/national sales and corporate finance at Glaxo/Glaxo Wellcome/GSK. His last position at GSK in 2001 was Vice President of Sales, CNS/GI Division. From 2001 to 2002, Mr. Hawley served as General Manager & Vice President of Sales and Marketing at Elan Pharmaceuticals in San Diego, and from 2002 to 2003, Mr. Hawley was the Chief Commercial Officer at Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company. From 2003 to 2006, he served as Executive Vice President of Commercial and Technical Operations for InterMune, Inc., a biopharmaceutical company focused on therapies in hepatology and pulmonology. Mr. Hawley has also served as a member of the board of directors of Cypress Bioscience (2007-2010) and Targeted Genetics (2006-2010), both previously publicly-traded pharmaceutical companies, as well as Alios BioPharma, Inc.

Sabrina Johnson

Ms. Sabrina Martucci Johnson serves as President, Chief Executive Officer, Secretary, Director of the company. Ms. Johnson founded Daré Operations and has served as its President, Chief Executive Officer, Secretary and a member of the Board of Directors since its inception. Ms. Johnson is a life sciences executive committed to advancing improvements in women’s healthcare. Prior to founding Daré Operations, Ms. Johnson was President of WomanCare Global Trading, a specialty pharmaceutical company in female reproductive healthcare with commercial product distribution in over 100 countries, from October of 2014 to May of 2015. Before serving as President of WomanCare Global Trading, Ms. Johnson provided financial consulting services to the WomanCare Global family of companies, including the for-profit Trading division as well as the United Kingdom-based non-profit division, from November of 2012 to July of 2013, when she joined full time as WomanCare’s Chief Financial Officer and Chief Operating Officer until becoming President of the Trading division. In addition, Ms. Johnson served as Chief Operating Officer and Chief Financial Officer of Cypress Bioscience, Inc. until its sale in 2010. Ms. Johnson also held marketing and sales positions with Advanced Tissue Sciences and Clonetics Corporation. She began her career in the biotechnology industry as a research scientist with Baxter Healthcare, Hyland Division, working on their recombinant factor VIII program.

Gregg Beloff

Mr. Gregg D. Beloff, J.D. serves as Principal Financial Officer of the Company. Mr. Beloff is a founder and Managing Director of Danforth Advisors, LLC, an advisory firm that provides financial, accounting and other operational services to life science companies, where he has served since 2011. During his time at Danforth, Mr. Beloff has served as the interim Chief Financial Officer for a number of companies in the life sciences industry. Mr. Beloff previously served as Chief Financial Officer at W2 Group, a social media marketing company, from April 2010 to March 2011, and as the Chief Financial Officer and Vice President of Archemix Corp., a biotechnology company, from December 2003 until August 2009. Prior to joining Archemix, Mr. Beloff served as Chief Financial Officer and Vice President of Finance at ImmunoGen Inc. a biotechnology company, from March 2001 to 2003. From 1998 to 2001, Mr. Beloff was Vice President of Investment Banking at Canaccord Genuity Inc. (formerly, Adams Harkness & Hill Inc. and Canaccord Adams). From 1993 to 1996, Mr. Beloff was an Attorney at the law firm of Gaffin & Krattenmaker P.C. Mr. Beloff received a J.D. from the University of Pittsburgh School of Law, an M.B.A. from Carnegie Mellon University and a B.A. in history from Middlebury College. Mr. Beloff has no family relationships with any of the executive officers or directors of the Company.

Lisa Walters-Hoffert

Ms. Lisa Walters-Hoffert serves as Chief Financial Officer of the company. Ms. Walters-Hoffert has served as Chief Business Officer of Daré Operations since its inception in 2015, and currently serves as Chief Financial Officer, a role she has served since March of 2017. During the 25 years prior to joining the team, Ms. Walters-Hoffert was an investment banker focused primarily on raising equity capital for, and providing advisory services to, small-cap public companies. Ms. Walters-Hoffert worked for Roth Capital Partners, an investment banking firm focused on providing investment banking services to such companies, from 2003 until January of 2015, where she most recently served as Managing Director in the Investment Banking Division, overseeing the firm’s San Diego office and its activities with respect to medical device, diagnostic and specialty pharma companies. At Roth Capital Partners, Ms. Walters-Hoffert trained and managed transaction deal teams and was responsible for the oversight of all aspects of transactions, including due diligence, internal communications with sales forces and external communications with institutional investors, among others. Ms. Walters-Hoffert has held various positions in the corporate finance and investment banking divisions of Citicorp Securities in San José, Costa Rica and Oppenheimer & Co, Inc. in New York City, New York. Ms. Walters-Hoffert has served as a member of the Board of Directors of the San Diego Venture Group, as Past Chair of the UCSD Librarian’s Advisory Board and as Immediate Past Chair of the Board of Planned Parenthood of the Pacific Southwest. Ms. Walters-Hoffert graduated from Duke University with a BS in Management Sciences, magna cum laude.

Jame O'Neill

James E. O'Neill is Principal Accounting Officer, Controller, Assistant Treasurer of the Company. Prior to joining the Company, Mr. O’Neill worked for Bruker Corporation, a scientific instruments and analytical and diagnostic solutions company, from 2005 to April 2012, serving as U.S. Controller of its subsidiaries Bruker BioSpin Corp., Bruker Daltonics, Inc., and Bruker Optics, Inc. from 2010 to April 2012 and U.S. Controller of its subsidiary Bruker Daltonics, Inc. from 2005 to 2010. From 2002 to 2005, Mr. O’Neill worked at Anika Therapeutics, Inc., an orthopedic medicines company, serving as Corporate Controller. Mr. O’Neill holds a B.S. in Business Administration from North Adams State College and is a Certified Management Accountant.

William Rastetter

Dr. William H. Rastetter, Ph.D., is Lead Independent Director of the Company. He has served as a director since January 2014 and as our lead independent director since April 2014. He is a Co-Founder of Receptos, Inc., a biopharmaceutical company, where he serves as Director and Chairman of the Board, and previously held the role of Acting Chief Executive Officer. Dr. Rastetter served as a Partner at the venture capital firm of Venrock Associates. Prior to his tenure with Venrock, Dr. Rastetter was Executive Chairman of Biogen Idec, from the merger of the two companies (Biogen and Idec Pharmaceuticals). He joined Idec Pharmaceuticals as Chairman and Chief Executive Officer. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and served as well in a scientific capacity at Genentech. Dr. Rastetter also serves as the Chairman of public life sciences companies Illumina, Inc., Neurocrine Biosciences, Inc., Fate Therapeutics Inc. and Receptos, Inc. and as a director of Regulus Therapeutics, Inc. Dr. Rastetter has held various faculty positions at the Massachusetts Institute of Technology and Harvard University and is an Alfred P. Sloan Fellow. Dr. Rastetter holds a B.S. from the Massachusetts Institute of Technology and received his M.A. and Ph.D. from Harvard University.

Steve Hall

Steven E. Hall, Ph.D., is Independent Director of the company. Dr. Hall has served as a director since 2010. Dr. Hall serves as a general partner at Lilly Ventures, the venture capital arm of Eli Lilly and Company and serves as President and Chief Executive Officer at privately held Esanex, Inc. Prior to joining Lilly Ventures, Dr. Hall was Senior Vice President, Research and Development, at Serenex, Inc., a biotechnology company (acquired by Pfizer), where he was also a co-founder. Dr. Hall has held multiple research management positions at companies including Eli Lilly, Sphinx Inc, and Bristol-Myers Squibb. Dr. Hall is the author of more than 40 papers and 60 patents. Dr. Hall currently sits on the boards of privately held life sciences companies FORMA Therapeutics, Inc., Esanex, Inc., Nimbus Discovery, LLC, Lysosomal Therapeutics, Inc., Numerate, Inc. and Hydra Biosciences, Inc. Dr. Hall received his B.S. from Central Michigan University and his Ph.D. from Massachusetts Institute of Technology.

Susan Kelley

Dr. Susan L. Kelley serves as Independent Director of the company. Dr. Kelley has served as our director since October 2014. Dr. Kelley has been developing drugs in oncology and immunology for over 25 years. She was previously Chief Medical Officer of the Multiple Myeloma Research Consortium and its sister organization, the Multiple Myeloma Research Foundation. Dr. Kelley has held positions of increasing responsibility at Bayer Healthcare Pharmaceuticals and Bayer-Schering Pharma, including Vice President, Global Clinical Development and Therapeutic Area Head—Oncology, where she led the Bayer team responsible for the development and worldwide regulatory approval of Nexavar® (sorafenib), including a renal cell carcinoma indication. She also held positions of increasing responsibility at Bristol-Myers Squibb in Oncology and Immunology drug development. She was a Fellow in Medical Oncology and Clinical Fellow in Medicine at Dana-Farber Cancer Institute, Harvard Medical School, and a Fellow in Medical Oncology and Pharmacology at Yale University School of Medicine, where she also served as a Clinical Assistant Professor of Medicine. Dr. Kelley currently serves as a member of the boards of directors of public oncology-focused biotechnology companies ArQule, Inc. and Alchemia, Pty Ltd. Dr. Kelley received her M.D. from Duke University School of Medicine.

Robin Steele

Dr. Robin J. Steele, J.D. LL.M serves as Independent Director of the company. Ms. Steele served as an advisor to Daré Operations since its inception in 2015. Ms. Steele previously served as Senior Vice President, General Counsel and Secretary of InterMune, Inc., a publicly traded biopharmaceutical company, from 2004 to 2014. Prior to her tenure with InterMune, Ms. Steele served as Vice President of Legal Affairs for North America for Elan Pharmaceuticals, a publicly traded pharmaceutical company, from 1998 to 2003. Ms. Steele currently serves on the board of directors of Alveo Technologies Inc., a privately held medical diagnostics company. Ms. Steele has previously served as a member of the board of directors of Alios Biopharma and Targanta Therapeutics, both of which were biotechnology companies focused on the research and development of therapeutic compounds prior to their respective acquisitions. Ms. Steele received a B.A. from the University of Colorado, a J.D. from the University of California, Hastings College of the Law, and an LL.M. in Taxation from New York University School of Law. The Board of Directors believes that Ms. Steele is qualified to serve on the Company’s Board of Directors due to her expertise in legal matters, her prior experience as general counsel of a public company and her involvement with a number of private biotechnology companies.